These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 9788400

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
    Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S.
    Int J Radiat Oncol Biol Phys; 2003 Jan 01; 55(1):78-92. PubMed ID: 12504039
    [Abstract] [Full Text] [Related]

  • 23. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM.
    Cancer Chemother Pharmacol; 1995 Jan 01; 35(4):304-12. PubMed ID: 7530173
    [Abstract] [Full Text] [Related]

  • 24. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
    Loong HH, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A.
    Eur J Cancer; 2014 Sep 01; 50(13):2263-70. PubMed ID: 24953566
    [Abstract] [Full Text] [Related]

  • 25. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
    Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E.
    J Clin Oncol; 2013 Mar 01; 31(7):853-9. PubMed ID: 23341517
    [Abstract] [Full Text] [Related]

  • 26. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
    Leyvraz S, Pasche P, Bauer J, Bernasconi S, Monnier P.
    J Clin Oncol; 1994 Sep 01; 12(9):1876-85. PubMed ID: 8083711
    [Abstract] [Full Text] [Related]

  • 27. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR.
    J Clin Oncol; 1994 Nov 01; 12(11):2351-9. PubMed ID: 7525886
    [Abstract] [Full Text] [Related]

  • 28. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
    Wibault P, Bensmaine MA, de Forni M, Armand JP, Tellez Bernal E, Guillot T, Recondo G, Domenge C, Janot F, Borel C, Luboinski B, Eschwege F, Cvitkovic E.
    J Clin Oncol; 1996 Apr 01; 14(4):1192-200. PubMed ID: 8648374
    [Abstract] [Full Text] [Related]

  • 29. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R, Vázquez S, Grau JJ, García-Sáenz JA, Lozano A, García C, Carles J, Irigoyen A, Mañós M, García-Paredes B, del Barco E, Taberna M, Escobar Y, Cruz JJ, Spanish Head and Neck Cancer Cooperative Group (TTCC).
    Int J Radiat Oncol Biol Phys; 2016 Feb 01; 94(2):289-96. PubMed ID: 26675064
    [Abstract] [Full Text] [Related]

  • 30. Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
    Oikawa H, Nakamura R, Nakasato T, Nishimura K, Sato H, Ehara S.
    Int J Radiat Oncol Biol Phys; 2009 Oct 01; 75(2):338-42. PubMed ID: 19735860
    [Abstract] [Full Text] [Related]

  • 31. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A, Abdel-Wahab M, Lewin A, Troner M, Rodrigues MA, Hamilton-Nelson KL, Markoe A.
    Int J Radiat Oncol Biol Phys; 2002 Jul 15; 53(4):942-7. PubMed ID: 12095561
    [Abstract] [Full Text] [Related]

  • 32. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S, Moras K, Pinto GJ, Bhat M, Hegde S, Sathian B, Luis NA.
    Asian Pac J Cancer Prev; 2014 Jul 15; 15(10):4147-52. PubMed ID: 24935361
    [Abstract] [Full Text] [Related]

  • 33. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
    Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O.
    Ann Oncol; 2017 Aug 01; 28(8):1917-1922. PubMed ID: 28498880
    [Abstract] [Full Text] [Related]

  • 34. [Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
    Gedouin D, Desprez P, Perron JJ, Fleury F, Leclech G, Miglianico L, Belpomme D, Chenal C.
    Bull Cancer Radiother; 1996 Aug 01; 83(2):104-7. PubMed ID: 8688215
    [Abstract] [Full Text] [Related]

  • 35. Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx.
    Wang HM, Hsueh CT, Wang CS, Chen IH, Liao CT, Tsai MH, Yeh SP, Chang JT.
    Anticancer Drugs; 2005 Apr 01; 16(4):447-53. PubMed ID: 15746582
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H, Tsukuda M, Taguchi T.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):789-94. PubMed ID: 17053926
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR.
    Semin Radiat Oncol; 1999 Apr 01; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.